Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
50
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors

Zexu Ni1 Department of Pathology, Dongguan Tungwah Hospital, Dongguan523110, People’s Republic of China
,
Lingling Zhang2 Department of Oncology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, People’s Republic of China;3 Department of Oncology, Peking University International Hospital, Beijing102206, People’s Republic of China
,
Jinhua Zheng1 Department of Pathology, Dongguan Tungwah Hospital, Dongguan523110, People’s Republic of China
,
Xiaojie Su1 Department of Pathology, Dongguan Tungwah Hospital, Dongguan523110, People’s Republic of China
&
Shucai Zhang2 Department of Oncology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, People’s Republic of ChinaCorrespondence[email protected]
Pages 9421-9425 | Published online: 06 Nov 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
  • Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. JNCCN. 2012;10(10):1236–1271.23054877
  • Baek MY, Ahn HK, Park KR, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2018;33(1):168–175. doi:10.3904/kjim.2015.15827093978
  • Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895–902. doi:10.1200/JCO.2011.40.117423341526
  • Bersinger NA, Birkhauser MH, Yared M, Wunder DM. Serum glycodelin pattern during the menstrual cycle in healthy young women. Acta Obstet Gynecol Scand. 2009;88(11):1215–1221. doi:10.3109/0001634090329426419900139
  • Alok A, Karande AA. The role of glycodelin as an immune-modulating agent at the feto-maternal interface. J Reprod Immunol. 2009;83(1–2):124–127. doi:10.1016/j.jri.2009.06.26119896207
  • Mandelin E, Lassus H, Seppala M, et al. Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res. 2003;63(19):6258–6264.14559812
  • Hautala LC, Greco D, Koistinen R, et al. Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients. Breast Cancer Res Treat. 2011;128(1):85–95. doi:10.1007/s10549-010-1065-y20676758
  • Schneider MA, Muley T, Kahn NC, et al. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. Oncotarget. 2016;7(44):71285–71297. doi:10.18632/oncotarget.1247427713145
  • Schneider MA, Granzow M, Warth A, et al. Glycodelin: a new biomarker with immunomodulatory functions in non-small cell lung cancer. Clin Cancer Res. 2015;21(15):3529–3540. doi:10.1158/1078-0432.CCR-14-246425901080
  • Schneider MA, Muley T, Weber R, et al. Glycodelin as a serum and tissue biomarker for metastatic and advanced NSCLC. Cancers. 2018;10(12). doi:10.3390/cancers10110400.
  • Kunert-Keil C, Steinmuller F, Jeschke U, Gredes T, Gedrange T. Immunolocalization of glycodelin in human adenocarcinoma of the lung, squamous cell carcinoma of the lung and lung metastases of colonic adenocarcinoma. Acta Histochem. 2011;113(8):798–802. doi:10.1016/j.acthis.2010.11.00921168900
  • Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15(4):613–617. doi:10.1093/annonc/mdh13615033669
  • Weber R, Meister M, Muley T, et al. Pathways regulating the expression of the immunomodulatory protein glycodelin in nonsmall cell lung cancer. Int J Oncol. 2019;54(2):515–526. doi:10.3892/ijo.2018.465430535430
  • Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev. 2014;40(6):716–722. doi:10.1016/j.ctrv.2014.03.00524759599
  • Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol. 2016;11(10):1718–1728. doi:10.1016/j.jtho.2016.05.01327237825

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.